Washington State Psychedelics Trial Targets PTSD And Alcohol Use Disorder, Mandated By Law May 23, 2023
Awakn Life Sciences’ Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66%… Jul 20, 2022
Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead… Jul 5, 2022
Awakn Life Sciences Appoints Biotech and Investment Veteran Dennis Purcell as a Special Advisor to the CEO Jun 7, 2022
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for ‘The Investor… May 24, 2022
Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and… Apr 13, 2022
